Actively Recruiting
Clinical Intervention of Idecalcitol Combined With Whey Protein Powder and Exercise for Sarcopenia
Led by Zhejiang Provincial People's Hospital · Updated on 2024-08-05
450
Participants Needed
5
Research Sites
154 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
This clinical trial is a multicenter, single-blind, prospective, randomized controlled clinical application study. Subjects who met the trial criteria and signed the informed consent form were randomly divided into a control group, an experimental group 1, and an experimental group 2. After enrollment, the control group underwent a comprehensive assessment of their underlying conditions by professional physicians and received routine interventions, including basic nutritional intervention program guidance, progressive resistance exercise intervention program guidance, safety precautions, and symptomatic treatment for different complications, for a total intervention period of 24 weeks. The experimental group 1, in addition to the interventions provided to the control group, received whey protein powder supplementation for 12 weeks. The experimental group 2, on the other hand, received both whey protein powder and eldecalcitol supplementation on top of the interventions given to the control group, also for 12 weeks. The entire intervention period lasted for 24 weeks. Through regular general assessments, blood tests, measurements of muscle mass, muscle strength, and physical function, as well as analyses of negative adverse events, statistical methods were employed to evaluate the safety and efficacy of the comprehensive intervention methods for sarcopenia.
CONDITIONS
Official Title
Clinical Intervention of Idecalcitol Combined With Whey Protein Powder and Exercise for Sarcopenia
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Age 30 or above
- Diagnosed with sarcopenia according to AWGS criteria
- Able to walk and willing to follow the comprehensive intervention plan
- Patient and family agree to participate and sign informed consent
You will not qualify if you...
- Resting systolic blood pressure over 200 mmHg or diastolic blood pressure over 100 mmHg
- Severe heart disease such as moderate to severe aortic valve stenosis, acute pericarditis, acute myocarditis, myocardial infarction, or uncontrollable arrhythmia
- Acute stroke within the past 2 years
- Severe airway obstruction
- Lower limb fractures in the past year or upper limb fractures in the past 6 months
- Hypercalcemia (corrected albumin serum calcium over 2.60 mmol/L)
- Active malignant tumors
- Chronic kidney disease stage 5
- Mental illness or severe cognitive impairment
- Long-term immobilization
- Other diseases interfering with evaluation of muscle mass, strength, or physical function
- Unable to cooperate with treatment
- Life expectancy less than 6 months
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 5 locations
1
The First People's Hospital of Chun'an County
Hangzhou, Zhejiang, China
Actively Recruiting
2
Zhejiang Provincial People's Hospital
Hangzhou, Zhejiang, China
Actively Recruiting
3
Huzhou Nanxun District People's Hospital
Huzhou, Zhejiang, China
Actively Recruiting
4
Xianju People's Hospital
Taizhou, Zhejiang, China
Actively Recruiting
5
Dinghai Central Hospital of Zhoushan City
Zhoushan, Zhejiang, China
Actively Recruiting
Research Team
J
Jianfeng Tu, Doctor
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
SINGLE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
3
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here